Legend Biotech Corporation (LEGN) - News Archive

In the rapidly evolving field of cell therapy, Legend Biotech Corporation stands out as a leader in innovation and sustainability. This article reviews the recent endeavors undertaken by Legend Biotech, including the of...

CARVYKTI s Impact on Minimal Residual Disease and Overall Survival in Multiple Myeloma: Insights from the CARTITUDE-4 Trial : The CARTITUDE-4 clinical trial data, conducted by Legend Biotech, highlights the efficacy of...

Revolutionizing Multiple Myeloma Treatment: Findings from the CARTITUDE-4 Trial Reveal Promising OutcomesMultiple myeloma, a malignancy of plasma cells in bone marrow, remains a formidable adversary in oncology, present...

Legend Biotech’s Strategic Appointments and Innovations in Cell TherapyIntroductionIn a rapidly transforming pharmaceutical landscape, Legend Biotech Corporation is making significant strides to solidify its position as...

The landscape of pharmaceutical sciences is rapidly evolving, particularly in the field of cell therapy. Advances in technology and significant investment in research and development are crucial for maintaining leadersh...

Multiple myeloma (MM) poses a significant clinical challenge, particularly when patients have relapsed or have become refractory to lenalidomide, a cornerstone in MM treatment. Current standard therapies include combina...

Automation and Innovation: Multiply Labs and Legend Biotech s New Breakthroughs in Cell Therapy ManufacturingSAN FRANCISCO and SOMERSET, N.J. In a groundbreaking collaboration set to redefine the landscape of cell thera...

Legend Biotech Announces Promising Advancement in Multiple Myeloma Treatment: Landmark Phase 3 CARTITUDE-4 Trial Showcases Positive Overall Survival Results for CARVYKTILegend Biotech, a global biotechnology leader, has...

:Legend Biotech Corporation, a renowned global leader in cell therapy, has unveiled groundbreaking results from the Phase 2 CARTITUDE-2 Cohort D study, showcasing the potential of CARVYKTI (ciltacabtagene autoleucel; ci...

Legend Biotech Corporation, a global leader in cell therapy, recently shared significant findings from the Phase 2 CARTITUDE-2 Cohort D study, highlighting the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta...

CSIMarket.com Legend Biotech Corporation (NASDAQ: LEGN), a renowned global leader in cell therapy, is making significant strides in the development of CAR-T cell therapy for patients with multiple myeloma. The company h...

Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in the field of cell therapy, recently made groundbreaking announcements regarding their CAR-T cell therapy, CARVYKTI (ciltacabtagene autoleucel, or cil...

SOMERSET, N.J. Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, is poised to make significant strides in the treatment of multiple myeloma through groundbreaking data and strategic collaborati...

Europe Greenlights Ciltacabtagene Autoleucel for Treatment of Relapsed and Refractory Multiple Myeloma: A Major Breakthrough in Oncotherapy In a significant move in the field of oncotherapy, the European Commission (EC)...

Legend Biotech, a prominent player in the field of cell therapy, recently obtained approval from the European Commission (EC) for its breakthrough treatment, CARVYKTI (ciltacabtagene autoleucel, cilta-cel), targeting ad...

SOMERSET, N.J. - In a significant development for patients suffering from relapsed or refractory multiple myeloma, CARVYKTI (ciltacabtagene autoleucel) has received a positive recommendation from the U.S. Food and Drug...

Legend Biotech Corporation (NASDAQ: LEGN), a renowned global leader in cell therapy, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommend...

Legend Biotech (NASDAQ: LEGN), a trailblazer in the world of biotechnology, is devoted to developing, producing, and marketing pioneering therapies created to battle life-threatening diseases and conditions.The closed l...

Legend Biotech Corporation, a global biotechnology company focused on developing novel therapies to combat life-threatening diseases, has made a significant stride in the field of CAR-T cell therapy. In a recent announc...